Services

Launching a first-in-class therapy for an ultra-rare condition: this was a new disease area for our client, and there was no licensed treatment available. Disease awareness was minimal, and so diagnosis rates were low. Our brief was to create an awareness among stakeholders for the need for treatment and develop the launch materials.

A mid-sized biotech client sought to develop and validate a payer value proposition for a first-in-class drug indicated for a rare form of dysmorphic short stature.

The condition was considered ‘low impact’ by many key stakeholders, leading to a reluctance to treat. Our challenge was to give a voice to those affected and overcome entrenched scepticism.

Our international pharmaceutical company client had two marketed haemophilia products that, although broadly reimbursed across Europe, were subject to frequent pricing and reimbursement discussions with payers.